FDA Holds Off Approval Of AstraZeneca Diabetes Treatment
AstraZeneca said Friday that the U.S. Food and Drug Administration has held off on approving its Type 2 diabetes treatment for adults with the combination of the drugs saxagliptin and dapagliflozin and...To view the full article, register now.
Already a subscriber? Click here to view full article